Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics (NASDAQ: BCTX) presented robust clinical data at ASCO 2025, showcasing impressive results from their Bria-IMT and Bria-OTS studies in metastatic breast cancer. The Phase 2 study demonstrated a median Overall Survival of 17.3 months for patients treated with the Phase 3 formulation since 2022, surpassing comparable literature outcomes. The treatment showed clinical benefit across all breast cancer subtypes with a 55% overall clinical benefit rate, including 100% in HER2+, 55% in HR+/HER2-, and 45% in triple-negative breast cancer patients. Notably, the Phase 3 formulation patients experienced significantly improved survival (13.9 vs 6.93 months) compared to alternate formulation. The therapy demonstrated strong safety with no treatment-related discontinuations, and efficacy data matched or exceeded FDA-approved therapies in similar patient populations. The company continues its pivotal Phase 3 study and has initiated combination therapy in its Bria-OTS program.

BriaCell Therapeutics (NASDAQ: BCTX) has announced significant progress in its Phase 1/2 study of Bria-OTS, a personalized immunotherapy for metastatic breast cancer. The therapy has successfully cleared its safety evaluation in the monotherapy setting and has now begun dosing patients in combination with checkpoint inhibitors. Notably, the first monotherapy patient showed complete resolution of lung metastasis and remains in the study.

The study will evaluate Bria-OTS with checkpoint inhibitors in up to 12 patients with metastatic breast cancer, focusing on safety and objective response rate as primary endpoints. This follows a successful three-patient monotherapy safety run-in. BriaCell also plans to evaluate Bria-OTS+, an optimized version, for multiple cancer types including breast and prostate cancers.

BriaCell Therapeutics (NASDAQ: BCTX) has announced positive Phase 2 survival and clinical benefit data for its Bria-IMT™ immunotherapy treatment for metastatic breast cancer. The study's Phase 3 formulation (n=37) demonstrated significant improvements in median overall survival (13.4 vs 6.9 months, P=0.01) and progression-free survival (3.6 vs 2.6 months, P=0.01) compared to alternate formulation. The treatment achieved a Clinical Benefit Rate of 61% and an Objective Response Rate of 14%, meeting or exceeding outcomes of FDA-approved therapies despite treating more heavily pre-treated patients. Notably, Bria-IMT showed strong safety with no treatment-related discontinuations. The company will present these results in three clinical poster presentations and one publish-only abstract at ASCO 2025, with 22% of patients still in active survival follow-up.

BriaCell Therapeutics (NASDAQ: BCTX) has provided significant updates on their cancer immunotherapy programs. Their lead candidate Bria-IMT™ is progressing well in a pivotal Phase 3 study for metastatic breast cancer, with over 75 patients enrolled across 54 clinical sites. The treatment has received Fast Track designation from the FDA. Phase 2 survival data has shown superior results compared to standard care treatments like TRODELVY® in hormone receptor positive (HR+) metastatic breast cancer patients, with 83% of evaluable patients showing clinical benefit. Additionally, their personalized Bria-OTS™ platform has demonstrated promising early results, including complete resolution of lung metastasis in their first treated breast cancer patient at 4-month follow-up. The company recently raised US$13.8 million through a public offering to support their clinical programs and operations.

BriaCell Therapeutics has reported promising Phase 3 data for its Bria-IMT™ treatment in metastatic breast cancer at AACR 2025. The study identified key biomarkers that could predict patient response to treatment, including positive delayed-type hypersensitivity (DTH) and favorable Neutrophil-to-Lymphocyte Ratio (NLR).

Early clinical data (n=62) showed median progression-free survival of 3.67 months across all arms. Notably, positive DTH correlated with better PFS (4.5 vs 2.5 months), while favorable NLR and lower Circulating Tumor Cells showed significant survival benefits. The Bria-IMT regimen demonstrated excellent tolerability with no treatment discontinuations.

The ongoing multicenter randomized study involves 57 US clinical sites, evaluating overall survival with Bria-IMT plus checkpoint inhibitor versus standard treatment. The trial, which received FDA Fast Track designation, will analyze interim data after 144 patient events, potentially leading to full approval for metastatic breast cancer treatment.

BriaCell Therapeutics, a clinical-stage biotech company focused on cancer immunotherapy, has successfully closed its public offering raising $13.8 million in gross proceeds. The offering consisted of 3,066,666 units, including 399,999 units from the full exercise of the underwriter's option.

Each unit, priced at $4.50, includes one common share (or pre-funded warrant) and one warrant. The warrants, trading under symbol BCTXZ on Nasdaq, allow holders to purchase one common share at $5.25 and expire in five years.

• ThinkEquity served as the sole book-running manager
• Offering was registered with SEC (Form S-1 File No. 333-286670)
• Funds will support working capital, corporate purposes, and business objectives

The transaction utilized the TSX Company Manual Section 602.1 exemption for eligible Nasdaq-interlisted issuers. The offering was conducted through a prospectus available via ThinkEquity and the SEC website.

BriaCell Therapeutics Corp. (NASDAQ: BCTX) has presented positive Phase 2 data for its Bria-IMT™ immunotherapy in metastatic breast cancer at AACR 2025. Key highlights include:

- Clinical benefit observed in 83% of patients receiving Phase 3 formulation
- Overall survival reached 17.3 months for HR+ patients and 11.44 months for triple negative breast cancer
- 50% overall response rate for patients with intracranial metastases, with 75% clinical benefit rate
- Clinical benefit rates ranging from 45% to 100% based on subtype

The study included 54 metastatic breast cancer patients, with 37 receiving the current Phase 3 formulation. Patients were heavily pre-treated with a median of 6 prior treatments. The company also presented data on its enhanced Bria-OTS+ platform, which includes additional immune-activating factors for breast and prostate cancer programs.

BriaCell Therapeutics (Nasdaq: BCTX) has announced the pricing of a $13.8 million public offering consisting of 3,066,666 units, including 399,999 units from the full exercise of the underwriter's option. Each unit, priced at $4.50, includes one common share (or pre-funded warrant) and one warrant.

The warrants, trading under symbol 'BCTXZ' from April 25, 2025, are immediately exercisable at $5.25 per share with a five-year expiration. The offering is expected to close on April 28, 2025. ThinkEquity serves as the sole book-running manager.

The company plans to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives.

BriaCell Therapeutics (Nasdaq: BCTX) has confirmed complete resolution of lung metastasis in their Phase 1/2a Bria-OTS study. The breakthrough was observed in a 78-year-old woman with hormone receptor positive (HR+) metastatic breast cancer who had previously failed multiple therapies.

The patient, enrolled on November 21, 2024, received Bria-OTS intradermal injections every 2 weeks for six weeks (4 doses), followed by dosing every 3 weeks. The treatment resulted in complete resolution of lung metastasis at 2 months, confirmed at 4 months follow-up, with stable disease maintained elsewhere.

The patient entered the study with extensive metastases in bone, lymph node, and lung. This response was achieved with the lowest dose level in the trial, demonstrating promising activity of the Bria-OTS platform as monotherapy. The Phase 1/2a dose escalation study (NCT06471673) will evaluate Bria-OTS both as monotherapy and in combination with an immune checkpoint inhibitor.